Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 20/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1008053 | 0.91 | TLR7 (0.62) | TLR7 | |
| SCHEMBL1058527 | 0.87 | TLR7 (0.58) | TLR7 | |
| SCHEMBL1060341 | 0.87 | TLR7 (0.59) | TLR7 | |
| SCHEMBL1006099 | 0.86 | TLR7 (0.76) | TLR7 | |
| SCHEMBL1008618 | 0.86 | TLR7 (0.60) | TLR7 | |
| SCHEMBL1056204 | 0.84 | TLR7 (0.55) | TLR7 | |
| SCHEMBL1063297 | 0.84 | TLR7 (0.59) | TLR7 | |
| SCHEMBL1008680 | 0.84 | TLR7 (0.73) | TLR7 | |
| SCHEMBL1007709 | 0.83 | TLR7 (0.58) | TLR7 | |
| SCHEMBL1062753 | 0.83 | TLR7 (0.58) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2268618-B1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | NOVARTIS AG (CH) | 2015-05-27 | — | — | EP | claimed |
| US-8895577-B2 | Compounds and compositions as TLR activity modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2014-11-25 | — | — | US | claimed |
| US-20130253002-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2013-09-26 | — | — | US | claimed |
| US-8466167-B2 | Compounds and compositions as TLR activity modulators | IRM LLC (BM) | 2013-06-18 | — | — | US | claimed |
| US-20110081365-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2011-04-07 | — | — | US | claimed |
| EP-2268618-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2011-01-05 | — | — | EP | claimed |
| WO-2009111337-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2009-09-11 | — | — | WO | claimed |
| US-20180333406-A1 | BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2018-11-22 | — | — | US | disclosed |
| EP-2440245-B1 | BENZONAPHTHYRIDINE-CONTAINING VACCINES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2017-12-06 | — | — | EP | disclosed |
| EP-2512478-B1 | HOMOGENEOUS SUSPENSION OF IMMUNOPOTENTIATING COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2017-04-19 | — | — | EP | disclosed |
| US-9597326-B2 | Benzonapthyridine compositions and uses thereof | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2017-03-21 | — | — | US | disclosed |
| US-20160375132-A1 | HOMOGENOUS SUSPENSION OF IMMUNOPOTENTIATING COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2016-12-29 | — | — | US | disclosed |
| US-9517263-B2 | Benzonaphthyridine-containing vaccines | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2016-12-13 | — | — | US | disclosed |
| WO-2011130379-A1 | BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF | NOVARTIS AG (CH) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011084549-A1 | HOMOGENEOUS SUSPENSION OF IMMUNOPOTENTIATING COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2011-07-14 | — | — | WO | disclosed |
| US-20110081365-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2011-04-07 | — | — | US | disclosed |
| US-20110081365-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2011-04-07 | — | — | US | disclosed |
| US-20110081365-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2011-04-07 | — | — | US | disclosed |
| EP-2268618-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2011-01-05 | — | — | EP | disclosed |
| WO-2010144734-A1 | BENZONAPHTHYRIDINE-CONTAINING VACCINES | NOVARTIS AG (CH) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130253002-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | TLR5, TLR8, TLR7 | TLR7 3/4885 |
| US-20160375132-A1 | HOMOGENOUS SUSPENSION OF IMMUNOPOTENTIATING COMPOUNDS AND USES THEREOF | CD14, ICOS, CD69 | TLR7 45/4885 |
| US-20110081365-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | TLR5, TLR8, TLR7 | TLR7 3/4885 |
| US-20180333406-A1 | BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF | HAMP, MAVS, MYD88 | TLR7 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.